Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐controlled studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included patients with radiographic axial SpA (anti–tumor necrosis factor [anti‐TNF]–naive patients and patients with inadequate response or intolerance to anti‐TNF, respectively); study 3 patients had nonradiographic axial SpA.

[1]  M. Soucek,et al.  AXIAL SPONDYLOARTHRITIS , 2023 .

[2]  D. Gladman,et al.  Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison , 2018, Nature Reviews Rheumatology.

[3]  J. Krueger,et al.  Psoriasis pathogenesis and the development of novel targeted immune therapies , 2017, The Journal of allergy and clinical immunology.

[4]  M. Brown,et al.  Pathogenesis of ankylosing spondylitis — recent advances and future directions , 2017, Nature Reviews Rheumatology.

[5]  I. Olivieri,et al.  Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies , 2017, Current Rheumatology Reports.

[6]  A. Gottlieb,et al.  Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2) , 2016, Annals of the rheumatic diseases.

[7]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[8]  A. Gottlieb,et al.  Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial , 2015, Arthritis care & research.

[9]  Erin Stevens,et al.  Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation. , 2015, Immunity.

[10]  T. Mcclanahan,et al.  Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. , 2015, Immunity.

[11]  G. Pucci,et al.  Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis , 2015, Expert opinion on biological therapy.

[12]  D. Dumitrascu,et al.  Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. , 2015, World journal of gastroenterology.

[13]  Aditya K. Gupta,et al.  COSENTYX (Secukinumab). , 2015, Skinmed.

[14]  A. Gottlieb,et al.  Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials , 2014, Annals of the rheumatic diseases.

[15]  A. Gottlieb,et al.  Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, , 2014, Annals of the rheumatic diseases.

[16]  J. Listing,et al.  Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS) , 2014, Annals of the rheumatic diseases.

[17]  M. Dougados,et al.  Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study , 2013, Annals of the rheumatic diseases.

[18]  R. Colbert,et al.  HLA-B27 misfolding and ankylosing spondylitis. , 2014, Molecular immunology.

[19]  D. Baeten,et al.  Inflammatory pathways in spondyloarthritis. , 2014, Molecular immunology.

[20]  Désirée van der Heijde,et al.  Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[21]  A. Gottlieb,et al.  Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial , 2013, The Lancet.

[22]  C. Loddenkemper,et al.  In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. , 2013, Arthritis and rheumatism.

[23]  R. Landewé,et al.  Comorbidities in patients with spondyloarthritis. , 2012, Rheumatic diseases clinics of North America.

[24]  T. Mcclanahan,et al.  IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells , 2012, Nature Medicine.

[25]  R. Valle-Oñate,et al.  Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis. , 2011, Clinical and experimental rheumatology.

[26]  C. Loddenkemper,et al.  Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response , 2011, Arthritis research & therapy.

[27]  M. Dougados,et al.  2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis , 2011, Annals of the rheumatic diseases.

[28]  R. Landewé,et al.  Extended Report , 2022 .

[29]  J. Goodall,et al.  Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[30]  D. M. van der Heijde,et al.  Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group , 2009, Annals of the rheumatic diseases.

[31]  M. Dougados,et al.  The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis , 2009, Annals of the rheumatic diseases.

[32]  M. Dougados,et al.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection , 2009, Annals of the rheumatic diseases.

[33]  M. Dougados,et al.  New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS) , 2009, Annals of the rheumatic diseases.

[34]  D. Wendling,et al.  Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients , 2009, Clinical Rheumatology.

[35]  D. Speiser,et al.  Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. , 2008, Arthritis and rheumatism.

[36]  M. Lebwohl,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) , 2008, The Lancet.

[37]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[38]  Simon C. Potter,et al.  Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants , 2007, Nature Genetics.

[39]  D. M. van der Heijde,et al.  Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems , 2004, Annals of the rheumatic diseases.

[40]  J J Anderson,et al.  Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. , 2001, Arthritis and rheumatism.

[41]  A. Calin,et al.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.

[42]  A. Calin,et al.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. , 1994, The Journal of rheumatology.

[43]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.